Evidence map›Paper›PMID 35111505›Full record

ArticleFujita medical journal2019

Preliminary therapeutic outcomes of using direct oral anticoagulants to treat venous thromboembolism in gynecological cancer patients.

Sayaka Osaki, Satoshi Kawai, Mayuko Ito, Sayaka Otani, Ryoko Ichikawa, Yutaka Torii, Hiroshi Takahashi, Hiroshi Toyama, Yukio Ozaki, Takuma Fujii

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Fujita medical journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sayaka OsakiDepartment of Obstetrics and Gynecology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Satoshi KawaiDepartment of Obstetrics and Gynecology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Mayuko ItoDepartment of Obstetrics and Gynecology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Sayaka OtaniDepartment of Obstetrics and Gynecology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Ryoko IchikawaDepartment of Obstetrics and Gynecology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Yutaka ToriiDepartment of Obstetrics and Gynecology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Hiroshi TakahashiFaculty of Rehabilitation, Fujita Health University, School of Health Sciences, Toyoake, Aichi, Japan.
Hiroshi ToyamaDepartment of Radiology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Yukio OzakiDepartment of Cardiology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Takuma FujiiDepartment of Obstetrics and Gynecology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Fujita Health University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesVenous thromboembolism (VTE) is often a problematic complication in patients with gynecological cancer. Despite increasing opportunities to use direct oral anticoagulants (DOACs) to treat VTE, there are no reports on the therapeutic outcomes of DOACs in patients with gynecological cancer; however, there are some studies on cancer patients in general. We retrospectively examined the efficacy and safety of using DOACs to treat VTE in such patients.

methodsThe study cohort comprised 43 patients with gynecological cancer and VTE who received treatment between May 2005 and April 2016. They were divided into two groups: DOACs used (DOAC group, n=21) and only unfractionated heparin (UFH) and warfarin used (standard group, n=22). The rates of improvement and recurrence of VTE and incidence of adverse events were compared between these groups.

resultsAt 6 months, the VTE of 85% of patients in the DOAC group and of 75% in the standard group had improved (

conclusionsRates of VTE improvement and of recurrence of VTE and adverse events did not differ significantly between the study groups.

Indexed as

Direct oral anticoagulantsGynecological cancerVenous thromboembolism

Identifiers

PMID35111505
PMCPMC8766242
OpenAlexW2966812483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.